How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?
about
Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low- and Middle-Income Countries: A Systematic Literature ReviewUniversal test, treat, and keep: improving ART retention is key in cost-effective HIV control in Uganda.Using the multiphase optimization strategy (MOST) to optimize an HIV care continuum intervention for vulnerable populations: a study protocol.Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.Sustainable HIV treatment in Africa through viral-load-informed differentiated care.Targeting an alcohol intervention cost-effectively to persons living with HIV/AIDS in East Africa.How inexpensive does an alcohol intervention in Kenya need to be in order to deliver favorable value by reducing HIV-related morbidity and mortality?Optimal timing of viral load monitoring during pregnancy to predict viraemia at delivery in HIV-infected women initiating ART in South Africa: a simulation study.Cost-effectiveness of routine viral load monitoring in low- and middle-income countries: a systematic review.Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India.Choice of time horizon critical in estimating costs and effects of changes to HIV programmes.The Effect of Monitoring Viral Load and Tracing Patients Lost to Follow-up on the Course of the HIV Epidemic in Malawi: A Mathematical Model.
P2860
Q28072167-AED061FE-F6CE-405E-BEEC-39FFCBAF6078Q33634785-AF6647A6-3C50-4B54-BF53-329BF8604CBEQ33640486-3C6EB298-5089-4621-8481-D869FAB5D93CQ35504333-0C2D7966-9AA7-4B90-A859-CC2E6889DE76Q35850530-3B8F0A5F-5A29-4368-A8EC-36C25A88CA41Q36915084-18280816-06F8-433C-AB47-52BD130C113CQ37064741-F81003E0-8DBB-4F96-9B3C-42BA496D59FDQ40954265-6AED0A75-27CB-4451-A9C8-D0324AC51307Q42381112-777C066E-25DB-4789-A22E-4887A026F61DQ46143181-0C711FC2-6544-49E9-8EE2-6278C38B6243Q47420352-C50D8067-70B5-4C09-8D80-52127A167568Q52604813-381E06E3-5214-44A6-A98A-DCAEF7B21B2AQ55088517-6629837D-E95A-4092-A531-E84DBA530D58Q55443840-266D915A-0E51-4EED-B99E-7785BDBE3977
P2860
How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
How do different eligibility g ...... testing in sub-Saharan Africa?
@ast
How do different eligibility g ...... testing in sub-Saharan Africa?
@en
type
label
How do different eligibility g ...... testing in sub-Saharan Africa?
@ast
How do different eligibility g ...... testing in sub-Saharan Africa?
@en
prefLabel
How do different eligibility g ...... testing in sub-Saharan Africa?
@ast
How do different eligibility g ...... testing in sub-Saharan Africa?
@en
P2093
P2860
P921
P1433
P1476
How do different eligibility g ...... testing in sub-Saharan Africa?
@en
P2093
Christopher Toohey
Daniel Keebler
Jason Kessler
Kimberly A Nucifora
Lauren M Uhler
Ronald Scott Braithwaite
Sherry M Mentor
P2860
P304
P356
10.1097/QAD.0000000000000110
P407
P478
28 Suppl 1
P577
2014-01-01T00:00:00Z